Scynexis (SCYX) Operating Income (2013 - 2026)
Scynexis (SCYX) posted Operating Income of -$16.9 million for Q1 2026, down 261.0% on a QoQ basis from $10.5 million in Q4 2025, and down 96.74% year-over-year from -$519.0 million in Q1 2025.
Scynexis (SCYX) Operating Income (2013 - 2026) Analysis & Trends
Scynexis' Operating Income history runs 14 years deep, the most recent figure standing at -$16.9 million for Q1 2026.
- Quarterly Operating Income fell 96.74% year-over-year to -$16.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.4 million (up 32.68% YoY) and the FY2025 annual result came in at -$16.1 million, up 56.69% from the prior year.
- Operating Income was -$16.9 million for Q1 2026 at Scynexis, down from $10.5 million in the prior quarter.
- Across five years, Operating Income topped out at $116.5 million in Q2 2023 and bottomed at -$23.1 million in Q4 2023.
- A 5-year average of -$4.9 million and a median of -$10.1 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income tumbled 1138.27% — and 2023, when it jumped 635.99%.
- Scynexis' Operating Income stood at -$22.5 million in 2022, then fell by 2.6% to -$23.1 million in 2023, then surged by 65.09% to -$8.1 million in 2024, then surged by 230.65% to $10.5 million in 2025, then plunged by 261.0% to -$16.9 million in 2026.
- Business Quant data shows SCYX's Operating Income at -$16.9 million in Q1 2026, $10.5 million in Q4 2025, and -$8.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | -16.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.94 Mn |
| Dec 31, 2025 | 10.52 Mn |
| Sep 30, 2025 | -8.41 Mn |
| Jun 30, 2025 | -9.56 Mn |
| Mar 31, 2025 | -8.61 Mn |
| Dec 31, 2024 | -8.05 Mn |
| Sep 30, 2024 | -10.32 Mn |
| Jun 30, 2024 | -9.24 Mn |
| Mar 31, 2024 | -9.51 Mn |
| Dec 31, 2023 | -23.07 Mn |
| Sep 30, 2023 | -10.10 Mn |
| Jun 30, 2023 | 116.51 Mn |
| Mar 31, 2023 | -10.68 Mn |
| Dec 31, 2022 | -22.48 Mn |
| Sep 30, 2022 | -21.80 Mn |
| Jun 30, 2022 | -21.74 Mn |
| Mar 31, 2022 | -19.74 Mn |
| Dec 31, 2021 | -22.30 Mn |
| Sep 30, 2021 | -19.44 Mn |
| Jun 30, 2021 | -17.51 Mn |